Related Experiment Video
Updated: Dec 25, 2025
Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes
Published on: September 24, 2013
Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human
Paul J M Wijnker1, Jolanda van der Velden2
1Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1117, Amsterdam, the Netherlands.
Insights
Hypertrophic cardiomyopathy (HCM) treatment is challenging due to diverse genetic causes. Understanding mutation-specific pathology is key to developing targeted therapies for this inherited heart condition.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a common inherited heart muscle disease.
- It leads to left ventricular hypertrophy, diastolic dysfunction, and sudden cardiac death in young individuals.
- Current pharmacological treatments to prevent or reverse HCM are limited.
Purpose of the Study:
- To review evidence for mutation-specific pathology in HCM.
- To explore mutation-specific treatment responses in HCM.
- To evaluate experimental models for studying HCM pathology and therapies.
Main Methods:
- Review of scientific literature on hypertrophic cardiomyopathy.
- Analysis of data from HCM patients, mouse models, and engineered heart tissue.
- Discussion of gene- and mutation-specific disease mechanisms.
Main Results:
- Over 1500 mutations are linked to HCM, primarily in sarcomere protein genes.
- Mutation-specific cellular perturbations contribute to HCM pathology.
- Treatment response may vary based on the underlying sarcomere gene mutation.
Conclusions:
- Personalized medicine approaches are needed for HCM, considering specific genetic mutations.
- Experimental models offer insights into mutation-specific HCM pathology and potential therapies.
- Further research is required to develop effective, mutation-targeted HCM treatments.
Abstract:
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is characterized by asymmetric left ventricular hypertrophy and diastolic dysfunction, and a frequent cause of sudden cardiac death at young age. Pharmacological treatment to prevent or reverse HCM is lacking. This may be partly explained by the variety of underlying disease causes. Over 1500 mutations have been associated with HCM, of which the majority reside in genes encoding sarcomere proteins, the cardiac contractile building blocks. Several mutation-mediated disease mechanisms have been identified, with proof for gene- and mutation-specific cellular perturbations. In line with mutation-specific changes in cellular pathology, the response to treatment may depend on the underlying sarcomere gene mutation. In this review, we will discuss evidence for mutation-specific pathology and treatment responses in HCM patients, mouse models and engineered heart tissue. The pros and cons of these experimental models for studying mutation-specific HCM pathology and therapies will be outlined.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care